References
- Hippert MM, O’Toole PS, Thorburn A. Autophagy in cancer: good, bad, or both? Cancer Res 2006;66:9349–9351.
- Bellodi C, Lidonnici MR, Hamilton A, . Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009;119:1109–1123.
- Lum JJ, Bauer DE, Kong M, . Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005;120:237–248.
- Amaravadi RK, Yu D, Lum JJ, . Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007;117:326–336.
- Smith CC, Shah NP. Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease. Hematology Am Soc Hematol Educ Program. 2011:121–127.
- Diamond JM, Melo JV. Mechanisms of resistance to BCR-ABL kinase inhibitors. Leuk Lymphoma 2011;52(Suppl. 1):12–22.
- Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 2011;95:761–791, viii.
- Nakamura M, Kikukawa Y, Takeya M, . Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 2010;37: 815–820.
- Gay F, Rajkumar V, Coleman M, . Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma. Am J Hematol 2010;85:664–669.
- Spahn JD, Fost DA, Covar R, . Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 2001;87:501–505.
- Biaxin based antibiotic therapy in previously untreated, advanced stage indolent lymphoma. [Accessed 1/6/12]. Available from: http://clinicaltrials.gov/
- Lenalidomide, dexamethasone and clarithromycin in treating patients who have undergone stem cell transplant for multiple myeloma. [Accessed 1/6/12]. Available from: http://clinicaltrials.gov/
- Carella AM, Beltrami G, Pica G, . Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma 2012;53:1409–1411.